Douglas E. Wood, MD, on Lung Cancer Screening: Status and Patient Selection
2016 NCCN Annual Conference (1)
Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.
Jaffer Ajani, MD, of The University of Texas MD Anderson Cancer Center, discusses the importance of HER2/neu testing and other aspects of treating patients with advanced gastroesophageal adenocarcinoma.
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
Wui-Jin Koh, MD, of the Fred Hutchinson Cancer Research Center, discusses the multiple services required to best treat this rare cancer.
Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.